Company Active LTD

Company profile

NRG Therapeutics Ltd

UK company 11294505, incorporated on 5 April 2018.

Home - NRG Therapeutics

NRG Therapeutics Ltd is a UK company with status Active founded in 2018 based in East of England.

Company number
11294505
Incorporated
5 Apr 2018
Companies House status
Active

Company identity

Founded / incorporated
5 April 2018

Company number 11294505

Verify at Companies House
Legal name
NRG THERAPEUTICS LTD
Company type
Private Limited Company
Region
East of England
Registered address
STEVENAGE BIOSCIENCE CATALYST
GUNNELS WOOD ROAD
STEVENAGE
HERTS
UNITED KINGDOM
SG1 2FX
Insolvency history
No

Latest accounts

Financial period: 1 May 2024 to 30 Apr 2025

FULLACCOUNTS
Turnover
Unknown
Profit / Loss
-£6,632,704
Employees
7

Company events

Reference milestones and recent Companies House filing stream events.

17 events
18 Apr
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

31 Jan
2027

Accounts due

Accounts Due

Next accounts due date

05 Aug
2026

Legacy

Miscellaneous

RP01SH01 | Transaction MzUzNTQ4MTc2MWFkaXF6a2N4

Published 05 Aug 2026 12:50

04 Aug
2026

Legacy

Miscellaneous

RP01SH01 | Transaction MzUzNTQ4MDg2MWFkaXF6a2N4

Published 04 Aug 2026 12:09

03 Aug
2026

Notification Of A Person With Significant Control Statement

Persons-with-significant-control

PSC08 | Transaction MzUzNjY3NzI0M2FkaXF6a2N4

Published 03 Aug 2026 11:52

03 Aug
2026

Cessation Of A Person With Significant Control

Persons-with-significant-control

PSC07 | Transaction MzUzNjY3NjExNGFkaXF6a2N4

Published 03 Aug 2026 11:45

28 Jul
2026

Replacement Filing Of Confirmation Statement With Made Up Date

Confirmation-statement

RP01CS01 | Transaction MzUzMjU0MTQ5MmFkaXF6a2N4

Published 28 Jul 2026 10:20

27 Jul
2026

Legacy

Miscellaneous

RP01SH01 | Transaction MzUzMjUzOTgxOWFkaXF6a2N4

Published 27 Jul 2026 15:05

27 Jul
2026

Legacy

Miscellaneous

RP01SH01 | Transaction MzUzMjUzOTMwNWFkaXF6a2N4

Published 27 Jul 2026 15:03

19 Apr
2026

Confirmation Statement

Confirmation-statement

CS01 | Transaction MzUxNjk5OTc0OGFkaXF6a2N4 | Paper/PDF filed

Published 31 Jul 2026 00:48

04 Apr
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

24 Feb
2026

Capital Allotment Shares

Capital

SH01 | Transaction MzUwNjg3MTI3NGFkaXF6a2N4 | Paper/PDF filed

Published 05 Aug 2026 22:51

27 Aug
2025

Capital Allotment Shares

Capital

SH01 | Transaction MzQ3ODgyMjI0M2FkaXF6a2N4 | Paper/PDF filed

Published 27 Jul 2026 23:10

15 Jul
2025

Capital Allotment Shares

Capital

SH01 | Transaction MzQ3MzcwMTU2OWFkaXF6a2N4 | Paper/PDF filed

Published 27 Jul 2026 23:12

30 Apr
2025

Accounts filed

Accounts

Last accounts made up date

14 May
2024

Capital Allotment Shares

Capital

SH01 | Transaction MzQyMTc1ODE2MGFkaXF6a2N4 | Paper/PDF filed

Published 07 Aug 2026 00:32

05 Apr
2018

Incorporated

Inception

Company registered at Companies House

Public funding

1 award
First funded
2022
Funded years
2022
Age at first award
4 years

Projects

2022 Collaborative R&D Lead participant

Development of Mitochondrial Permeability Transition Pore Inhibitors for the Treatment of Neurodegenerative Diseases

1 May 2022 to 30 Apr 2024

Awarded
£1,876,420
Total cost £2,680,600

Although life expectancy has increased steadily following major advances in public health and the development of modern medicines development, _healthy_ life expectancy has not increased to the same degree. Consequently, the UK's aging population is facing a crisis of extended periods of ill health in later life, with older adults often developing one or ...

Product types

Collaborative R&D